Cara Therapeutics Inc (OQ:CARA)

Apr 02, 2024 07:00 am ET
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive...
Mar 07, 2024 07:00 am ET
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual key opinion leader...
Mar 04, 2024 04:01 pm ET
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the...
Feb 12, 2024 04:01 pm ET
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate...
Jan 22, 2024 07:00 am ET
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the...
Dec 18, 2023 07:00 am ET
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KIND 1...
Nov 13, 2023 04:01 pm ET
Cara Therapeutics Reports Third Quarter 2023 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the...
Nov 02, 2023 07:00 am ET
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced it has entered into a Royalty Interest Purchase and Sale...
Oct 23, 2023 07:00 am ET
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio...
Sep 25, 2023 07:00 am ET
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co.,...
Sep 05, 2023 07:00 am ET
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive...
Aug 07, 2023 04:01 pm ET
Cara Therapeutics Reports Second Quarter 2023 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the...
Aug 03, 2023 07:00 am ET
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Helen M. Boudreau to its Board of...
Aug 02, 2023 07:00 am ET
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive...
Jul 24, 2023 07:00 am ET
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio...
Jun 02, 2023 06:46 pm ET
Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, June 2, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Tuesday, June 20, to coincide with the quarterly rebalance. The U.S. equity markets will be closed on Monday, June 19 in observance of the Juneteenth holiday. The changes ensure each index is more representative of its market capitalization range. All companies moving to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies movi
Jun 01, 2023 07:00 am ET
Cara Therapeutics to Present at the Jefferies Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive...
May 18, 2023 02:00 am ET
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis
May 18, 2023 02:00 am ET
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis
May 18, 2023 02:00 am ET
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe...
May 15, 2023 04:01 pm ET
Cara Therapeutics Reports First Quarter 2023 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the...
May 01, 2023 07:00 am ET
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio...
Apr 10, 2023 07:00 am ET
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive...
Mar 14, 2023 07:00 am ET
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today released its inaugural Environmental, Social, and Governance (ESG)...
Mar 06, 2023 04:01 pm ET
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the...
Feb 21, 2023 07:00 am ET
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio...
Feb 08, 2023 05:00 pm ET
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the New England Journal of Medicine (NEJM) has published...
Jan 17, 2023 07:00 am ET
Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host an in-person and virtual Capital...
Jan 03, 2023 07:00 am ET
Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive...
Nov 29, 2022 07:30 am ET
KemPharm Announces Appointment of Christopher Posner as New Independent Director
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal...
Nov 07, 2022 04:01 pm ET
Cara Therapeutics Reports Third Quarter 2022 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the...
Nov 03, 2022 07:00 am ET
Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board...
Nov 02, 2022 07:00 am ET
Cara Therapeutics to Present at Upcoming Investor Conferences
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that members of its Executive Leadership Team will...
Oct 24, 2022 07:00 am ET
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio...
Oct 10, 2022 04:05 pm ET
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics
Milestone payment highlights ongoing clinical progress of Oral KORSUVA™
Sep 28, 2022 07:00 am ET
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co.,...
Sep 12, 2022 07:00 am ET
Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial...
Sep 08, 2022 08:15 am ET
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced results from the KOMFORT Phase 2 clinical trial of oral...
Sep 06, 2022 07:00 am ET
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive...
Aug 24, 2022 07:00 am ET
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual event focused on...
Aug 22, 2022 07:00 am ET
Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced data from the KOMFORT Phase 2 clinical trial evaluating...
Aug 19, 2022 01:00 am ET
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
associated pruritus in hemodialysis patients Therapy recently approved in Canada under the brand name KORSUVA® Regulatory decisions in Australia and Singapore expected by the end of 2022 ST. GALLEN, Switzerland, and STAMFORD, Conn., Aug....
Aug 08, 2022 04:01 pm ET
Cara Therapeutics Reports Second Quarter 2022 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the...
Aug 03, 2022 07:00 am ET
Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive...
Aug 01, 2022 04:01 pm ET
Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio...
Jun 30, 2022 07:00 am ET
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced positive topline results from its Phase 2...
May 17, 2022 07:00 am ET
Cara Therapeutics to Present at Upcoming Investor Conferences
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief...
May 09, 2022 04:01 pm ET
Cara Therapeutics Reports First Quarter 2022 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for...
May 03, 2022 04:01 pm ET
Cara Therapeutics to Present at May Investor Conferences
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief...
Apr 29, 2022 07:00 am ET
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live...
Apr 28, 2022 01:00 am ET
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
associated pruritus in hemodialysis patientsFirst launches in Europe expected in H2 2022 ST. GALLEN, Switzerland and STAMFORD, Conn., April 28, 2022 (GLOBE NEWSWIRE) --  Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics,...
Apr 05, 2022 07:00 am ET
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief...
Apr 04, 2022 04:01 pm ET
Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2...
Mar 28, 2022 07:00 am ET
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced data from a sub-study of the KARE Phase 2...
Mar 08, 2022 04:01 pm ET
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KARE Phase 2 clinical...
Mar 01, 2022 04:01 pm ET
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for...
Feb 25, 2022 07:15 am ET
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of Kapruvia® (difelikefalin) for the treatment of...
Feb 22, 2022 04:01 pm ET
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live...
Feb 18, 2022 07:00 am ET
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual research and...
Jan 10, 2022 08:00 am ET
Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi...
Jan 03, 2022 04:01 pm ET
Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief...
Dec 20, 2021 07:00 am ET
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection
Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted Transitional Drug Add-On Payment Adjustment (TDAPA) to KORSUVA™ (difelikefalin) injection in the anti-pruritic...
Nov 30, 2021 08:31 am ET
Thinking about buying stock in Cara Therapeutics, RedHill Biopharma, Beyondspring, ATI Physical Therapy, or Co-Diagnostics?
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CARA, RDHL, BYSI, ATIP, and CODX.
Nov 18, 2021 08:30 am ET
Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors,...
Nov 09, 2021 04:30 pm ET
Cara Therapeutics to Present at Upcoming Investor Conferences
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that...
Nov 08, 2021 04:01 pm ET
Cara Therapeutics Reports Third Quarter 2021 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced...
Nov 03, 2021 08:00 am ET
Cara Therapeutics Announces CEO Transition
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that...
Nov 01, 2021 04:15 pm ET
Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the...
Oct 04, 2021 07:00 am ET
Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, presented results from...
Sep 29, 2021 07:00 am ET
Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced...
Sep 24, 2021 07:00 am ET
Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced...
Aug 24, 2021 08:30 am ET
Thinking about buying stock in Cara Therapeutics, Rekor Systems, Arcimoto, OpGen, or Easterly Government Properties?
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CARA, REKR, FUV, OPGN, and DEA.
Aug 23, 2021 03:41 pm ET
Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
Cara Therapeutics (Nasdaq: CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA™ (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney...
Aug 23, 2021 09:31 am ET
Thinking about buying stock in Xeris Pharmaceuticals, Cara Therapeutics, Bitfarms, Marathon Digital, or Pixelworks?
NEW YORK, Aug. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XERS, CARA, BITF, MARA, and PXLW.
Aug 09, 2021 04:01 pm ET
Cara Therapeutics Reports Second Quarter 2021 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced...
Aug 02, 2021 04:01 pm ET
Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the...
Jun 11, 2021 07:30 am ET
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics
DALLAS, June 11, 2021 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma, received a $10 million milestone payment from Cara Therapeutics (Nasdaq: CARA) related to the license agreement for the Peptelligence® oral formulation technology utilized in Oral KORSUVA™, the oral formulation of Cara's first-in-class KOR agonist, CR845/difelikefalin. Enteris is entitled to retain $3.9 million of this payment per the co
May 25, 2021 07:00 am ET
Cara Therapeutics to Present at the Jefferies Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that...
May 10, 2021 04:01 pm ET
Cara Therapeutics Reports First Quarter 2021 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced...
May 06, 2021 04:01 pm ET
Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that...
May 03, 2021 04:01 pm ET
Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the...
Apr 29, 2021 07:00 am ET
Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Apr 07, 2021 04:01 pm ET
Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Mar 31, 2021 07:00 am ET
Cara Therapeutics to Host Virtual Research and Development Event on April 7, 2021
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Mar 30, 2021 01:00 am ET
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency (EMA) accepted to review the Marketing Authorization Application (MAA) for difelikefalin injection for...
Mar 08, 2021 01:00 am ET
Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
Cara Therapeutics (Nasdaq:CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for...
Feb 25, 2021 04:01 pm ET
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced...
Feb 18, 2021 04:01 pm ET
Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the...
Feb 16, 2021 09:45 am ET
Should you invest in Cara Therapeutics, Applied Materials, Caterpillar, Roku, or Alibaba?
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CARA, AMAT, CAT, ROKU, and BABA.
Jan 11, 2021 07:00 am ET
Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia Paresthetica
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the...
Jan 06, 2021 07:00 am ET
Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Dec 28, 2020 07:00 am ET
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Dec 24, 2020 06:30 am ET
SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics
DALLAS, Dec. 24, 2020 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma, received a second milestone payment of $2.5 million from Cara Therapeutics (Nasdaq: CARA) related to the license agreement for Peptelligence® oral formulation technology utilized in Oral KORSUVA™, the oral formulation of Cara's first-in-class KOR agonist, CR845/difelikefalin.  SWK is entitled to receive $1.5 million of this payment per t
Dec 22, 2020 04:05 pm ET
CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced the appointment of...
Dec 02, 2020 07:00 am ET
Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Nov 11, 2020 07:00 am ET
Cara Therapeutics to Present at Multiple Upcoming Investor Conferences
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Nov 09, 2020 04:01 pm ET
Cara Therapeutics Reports Third Quarter 2020 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced...
Nov 02, 2020 04:01 pm ET
Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the...
Oct 27, 2020 04:05 pm ET
SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milestone Payment from Cara Therapeutics
DALLAS, Oct. 27, 2020 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma, received a milestone payment of $2.5 million from Cara Therapeutics (Nasdaq: CARA) related to the license agreement for Peptelligence® oral formulation technology utilized in Oral KORSUVA™, the oral formulation of Cara's first-in-class KOR agonist, CR845/difelikefalin.  SWK is entitled to receive $1.5 million of this payment per the cont
Oct 21, 2020 04:01 pm ET
Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that...
Oct 20, 2020 01:00 am ET
Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritus
Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq:CARA) today announced that both companies have signed a license agreement for commercialization of Korsuva (difelikefalin) Injection (“IV Korsuva”) for the treatment of chronic kidney...
Oct 01, 2020 07:00 am ET
Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the...
Aug 10, 2020 04:01 pm ET
Cara Therapeutics Reports Second Quarter 2020 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced...
Aug 06, 2020 04:01 pm ET
Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Aug 03, 2020 04:01 pm ET
Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Jun 30, 2020 07:00 am ET
Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Jun 17, 2020 07:00 am ET
Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
Patient enrollment increased approximately 28% to maintain >80% statistical power for primary endpoint and key registration endpoint of  >- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and...
May 27, 2020 04:01 pm ET
Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
May 11, 2020 04:01 pm ET
Cara Therapeutics Reports First Quarter 2020 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
May 07, 2020 07:00 am ET
Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
May 04, 2020 04:01 pm ET
Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the...
Apr 21, 2020 01:30 am ET
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection in Hemodialysis Patients with Pruritus
Statistically significant improvement in key secondary endpoint of proportion of patients with four point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.01) -KORSUVA Injection NDA and MAA submission expected in the...
Apr 08, 2020 07:00 am ET
Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Mar 25, 2020 07:00 am ET
Cara Therapeutics Reports Clinical Updates
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Feb 27, 2020 04:01 pm ET
Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced...
Feb 20, 2020 04:01 pm ET
Cara Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the...
Jan 08, 2020 04:01 pm ET
Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a...
Dec 06, 2019 04:01 pm ET
Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the...
Dec 03, 2019 04:01 pm ET
Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a...
Dec 03, 2019 07:00 am ET
Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced positive...
Nov 12, 2019 04:01 pm ET
Cara Therapeutics to Present at November Investor Conferences
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced company...
Nov 11, 2019 07:00 am ET
Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of Medicine
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the...
Nov 05, 2019 04:01 pm ET
Cara Therapeutics Reports Third Quarter 2019 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial...
Nov 01, 2019 07:00 am ET
Cara Therapeutics Announces Presentations at Kidney Week 2019
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced a...
Oct 29, 2019 04:01 pm ET
Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the...
Oct 14, 2019 07:00 am ET
Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA™ Injection in Hemodialysis Patients with Pru
Patient enrollment increased approximately 20% to maintain >- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by...
Sep 26, 2019 04:01 pm ET
Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a...
Aug 21, 2019 07:04 am ET
Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™
BOONTON, N.J., Aug. 21, 2019 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, today announced its entry into a definitive licensing agreement with Cara Therapeutics (Nasdaq: CARA) for Enteris' Peptelligence® technology in the ongoing development of an oral formulation of Cara's first-in-class KOR agonist, CR845/difelikefalin (KORSUVA™).  Peptelligence® is Enteris' proprietary platform for the oral delivery of peptides and BCS class II, III and IV small molecules.
Aug 21, 2019 07:00 am ET
Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today...
Aug 07, 2019 04:01 pm ET
Cara Therapeutics Reports Second Quarter 2019 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial...
Jul 31, 2019 04:01 pm ET
Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the...
Jul 29, 2019 04:01 pm ET
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today...
Jul 24, 2019 08:42 pm ET
Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock
Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today...
Jul 24, 2019 04:01 pm ET
Cara Therapeutics Announces Proposed Offering of Common Stock
Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today...
Jul 22, 2019 07:00 am ET
Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the...
Jul 11, 2019 08:30 am ET
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis
BOONTON, N.J., July 11, 2019 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful initiation of its Phase 2 clinical trial of Oral KORSUVA™ (CR845/difelikefalin) for the treatment of pruritus in patients with atopic dermatitis (AD). The tablet formulation of Oral KORSUVA, which was engineered using Enteris' proprietary oral peptide delivery technology, Peptelligence®, is now the subject of three separate, pruritus-focused Phase 2
Jul 09, 2019 07:00 am ET
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the...
Jun 26, 2019 07:00 am ET
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the...
May 31, 2019 07:00 am ET
Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a...
May 29, 2019 07:00 am ET
Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today...
May 08, 2019 04:01 pm ET
Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a...
May 07, 2019 04:01 pm ET
Cara Therapeutics Reports First Quarter 2019 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting peripheral kappa opioid receptors, today...
Apr 30, 2019 04:01 pm ET
Cara Therapeutics to Announce First Quarter 2019 Financial Results on May 7, 2019
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today...
Apr 02, 2019 04:01 pm ET
Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today...
Mar 29, 2019 07:20 am ET
Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics — Research Highlights Growth, Revenue, and Consolidated Resu
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of American Water Works Company, Inc. (NYSE:AWK), TripAdvisor, Inc....
Mar 12, 2019 04:01 pm ET
Cara Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting peripheral kappa opioid receptors, today...
Mar 05, 2019 04:01 pm ET
Cara Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today...
Feb 15, 2019 08:20 am ET
Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Cara Therapeutics, EnPro Industries, and K12 — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tenaris S.A. (NYSE:TS), Rapid7, Inc. (NASDAQ:RPD), Halozyme...
Jan 24, 2019 08:10 am ET
Consolidated Research: 2019 Summary Expectations for First Data, IDEXX Laboratories, CMS Energy, Worthington Industries, Triumph Group, and Cara Therapeutics — Fundamental Analysis, Key Performance In
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of First Data Corporation (NYSE:FDC), IDEXX Laboratories, Inc....
Jan 07, 2019 07:00 am ET
Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA™ (CR845/ difelikefalin) Injection in Hemodialysis Patients with Pruritus
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today...
Jan 02, 2019 07:00 am ET
Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today...
Nov 12, 2018 08:20 am ET
Research Report Identifies DXP Enterprises, Diebold Nixdorf, Fitbit, Nevro, Plains All American Pipeline, and Cara Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movemen
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of DXP Enterprises, Inc. (NASDAQ:DXPE), Diebold Nixdorf, Incorporated...
Nov 08, 2018 04:01 pm ET
Cara Therapeutics to Present at November Investor Conferences
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Nov 06, 2018 04:01 pm ET
Cara Therapeutics Reports Third Quarter 2018 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Oct 30, 2018 04:01 pm ET
Cara Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Oct 23, 2018 07:00 am ET
Cara Therapeutics Appoints Joana Goncalves, M.D., as Chief Medical Officer
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today...
Oct 18, 2018 08:55 am ET
Investor Expectations to Drive Momentum within Teradata, Liberty TripAdvisor, CPI Card Group, Cara Therapeutics, Ocular Therapeutix, and G-III Apparel Group, LTD — Discovering Underlying Factors of In
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Teradata Corporation (NYSE:TDC), Liberty TripAdvisor Holdings, Inc....
Sep 26, 2018 04:01 pm ET
Cara Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced a...
Sep 05, 2018 04:01 pm ET
Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced a...
Aug 27, 2018 07:40 am ET
Analysis: Positioning to Benefit within C&J Energy Services, LivePerson, Kadmon, Cara Therapeutics, CorMedix, and Second Sight Medical Products — Research Highlights Growth, Revenue, and Consolidated
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of C Energy Services, Inc. (NYSE:CJ), LivePerson, Inc. (NASDAQ:LPSN),...
Aug 07, 2018 04:01 pm ET
Cara Therapeutics Reports Second Quarter 2018 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Aug 07, 2018 07:00 am ET
Cara Therapeutics Doses First Patient in Second Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Aug 06, 2018 07:00 am ET
Cara Therapeutics Appoints Christopher A. Posner to Board of Directors
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Jul 31, 2018 04:05 pm ET
Cara Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018
Cara Therapeutics, Inc. (Nasdaq:CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today...
Jul 23, 2018 04:02 pm ET
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Cara Therapeutics, Inc. (Nasdaq:CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today...
Jul 19, 2018 08:00 am ET
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™
BOONTON, N.J, July 19, 2018 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful initiation of its Phase 2 clinical trial of Oral KORSUVA™ (CR845) in patients with pre-dialysis chronic kidney disease (CKD). The tablet formulation of Oral KORSUVA was engineered using Enteris' proprietary oral peptide delivery technology, Peptelligence®.
Jul 18, 2018 08:53 pm ET
Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock
Cara Therapeutics, Inc. (Nasdaq:CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today...
Jul 17, 2018 04:23 pm ET
Cara Therapeutics Announces Proposed Offering of Common Stock
Cara Therapeutics, Inc. (Nasdaq:CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today...
Jul 11, 2018 07:00 am ET
Cara Therapeutics Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Stage III-V Chronic Kidney Disease (CKD) Patients
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Jun 27, 2018 09:31 am ET
Thinking about buying stock in Alibaba, Cara Therapeutics, China Lending, Helios and Matheson Analytics Inc., or World Wrestling Entertainment?
CHICAGO, June 27, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, CARA, CLDC, HMNY, and WWE.
Jun 27, 2018 07:00 am ET
Cara Therapeutics Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845 in Patients Undergoing Abdominal Surgery
I.V. CR845 treatment resulted in statistically significant reductions in the secondary endpoint of incidence of nausea and vomiting at 24-hours post-surgery for both the 0.5 and 1.0 mcg doses (p=0.006; p0.0001 respectively)- -Cara to host...
Jun 21, 2018 07:35 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Camden National, Cara Therapeutics, Albany International, Emerge Energy Services LP, Fiesta Restaurant Group, and Resources Connecti
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Camden National Corporation (NASDAQ:CAC), Cara Therapeutics, Inc....
May 29, 2018 04:30 pm ET
Cara Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
May 23, 2018 09:31 am ET
Thinking about buying stock in Cara Therapeutics, Lowes, Neovasc Inc., Tiffany & Company or Target?
NEW YORK, May 23, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CARA, LOW, NVCN, TGT, and TIF.
May 23, 2018 06:00 am ET
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus
Cara Therapeutics, Inc. (Nasdaq:CARA), a U.S. biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today...
May 14, 2018 04:01 pm ET
Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting 
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
May 09, 2018 04:01 pm ET
Cara Therapeutics Reports First Quarter 2018 Financial Results
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
May 02, 2018 04:30 pm ET
Cara Therapeutics to Announce First Quarter 2018 Financial Results on May 9, 2018
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Apr 30, 2018 08:15 am ET
Research Report Identifies Cara Therapeutics, MGE Energy, IDEXX Laboratories, Sterling Construction, TTM Technologies, and Regis with Renewed Outlook — Fundamental Analysis, Calculating Forward Moveme
NEW YORK, April 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cara Therapeutics, Inc. (NASDAQ:CARA), MGE Energy...
Apr 10, 2018 07:00 am ET
Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation
STAMFORD, Conn., April 10, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Mar 22, 2018 07:35 am ET
Research Report Identifies Preferred Apartment Communities, Ubiquiti Networks, Infinity Property and Casualty, Cara Therapeutics, BP Prudhoe Bay Royalty Trust, and Mesabi Trust with Renewed Outlook —
NEW YORK, March 22, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Preferred Apartment Communities, Inc. (NYSE:APTS), Ubiquiti...
Mar 15, 2018 04:01 pm ET
Mar 08, 2018 04:30 pm ET
Cara Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018
STAMFORD, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Mar 01, 2018 07:02 am ET
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of Oral KORSUVA™
BOONTON, N.J., March 1, 2018 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful initiation of the Phase 1 clinical trial of its oral formulation of CR845/difelikefalin (KORSUVA™) in patients with chronic liver disease (CLD). The oral tablet formulation of KORSUVA was engineered using Enteris' proprietary oral peptide and small molecule delivery technology, Peptelligence®.
Feb 28, 2018 07:00 am ET
Feb 07, 2018 04:01 pm ET
Cara Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
STAMFORD, Conn., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Jan 23, 2018 08:30 am ET
Report: Developing Opportunities within TrustCo Bank Corp NY, Actua, Cara Therapeutics, Cabot Oil & Gas, Astronics, and Central Garden & Pet — Future Expectations, Projections Moving into 2018
NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of TrustCo Bank Corp NY (NASDAQ:TRST), Actua...
Nov 08, 2017 04:01 pm ET
Cara Therapeutics to Present at November Investor Conferences
STAMFORD, Conn., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced...
Nov 02, 2017 04:01 pm ET
Cara Therapeutics Reports Third Quarter 2017 Financial Results
Management to host conference call today at 4:30 p.m. ET
Oct 31, 2017 09:02 am ET
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence™-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patie
BOONTON, N.J., Oct. 31, 2017 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful initiation of its Phase 1 clinical trial of its oral formulation of CR845 in patients with stage III-V chronic kidney disease (CKD) who are not on dialysis. An oral tablet formulation of Cara Therapeutics' peripherally selective kappa opioid agonist CR845, was engineered using Enteris' proprietary oral delivery technology, Peptelligence™.
Oct 17, 2017 04:01 pm ET
Cara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017
STAMFORD, Conn., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at ANESTHESIOLOGY® 2017, the American Society of Anesthesiologists’ annual meeting, to be held October 21-25, 2017 in Boston....
Oct 04, 2017 04:01 pm ET
Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference
STAMFORD, Conn., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Joseph Stauffer, Chief Medical Officer, will present previously announced results from the Phase 2b trial of Oral CR845 in patients with osteoarthritis of the knee or hip at the Janney Montgomery Scott Osteoarthritis Pain Conference on Wednesday, October 11, 2017, at 11:15 a.m. ET in New Yo...
Aug 31, 2017 08:00 am ET
Cara Therapeutics to Participate in September Medical Meetings
Data from Phase 2 chronic osteoarthritis pain study of Oral CR845 to be presented in poster session at PAINWeek STAMFORD, Conn., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at PAINWeek, to be held September 5-9, 2017 in Las Vegas, NV and the American Association of Nurse Anesthetists (AANA) Nurse Anesthesia Annual Congress, to be hel...
Aug 03, 2017 08:00 am ET
Cara Therapeutics to Webcast Presentation at the Canaccord Genuity 37th Annual Growth Conference
STAMFORD, Conn., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the Canaccord Genuity 37th Annual Growth Conference on Thursday, August 10, 2017, at 8:00 a.m. ET in Boston....
Jul 27, 2017 04:30 pm ET
Cara Therapeutics to Announce Second Quarter 2017 Financial Results on August 3, 2017
STAMFORD, Conn., July 27, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, August 3, 2017, at 4:30 p.m. ET to report second quarter 2017 financial results and provide a corporate update....
Jul 20, 2017 10:00 am ET
The Next Gold Rush is Green
LONDON, July 20, 2017 /PRNewswire/ --

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.